---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-009629"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:22:36.056261+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics reports 2022 net loss of $41.7M; Phase 2 PEAK trial enrollment complete

## Summary
- Net loss of $41.7M for 2022, improved from $84.4M in 2021; net loss per share $4.43.
- Total revenues $18.1M, up from $5.4M, driven by $14.5M upfront from AVTX-007 out-license.
- Cash and equivalents $13.2M at Dec 31, 2022; raised $13.7M net in Feb 2023 public offering.
- Completed enrollment of Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma (91 patients); topline data expected Q2 2023.
- Identified lead molecule for AVTX-008 (BTLA agonist); target IND submission in 2024.

## SEC filing metadata
- accession: 0001628280-23-009629
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/0001628280-23-009629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/avtx-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-009629
- JSON: https://secwatch.observer/filing/0001628280-23-009629.json
- Plain text: https://secwatch.observer/filing/0001628280-23-009629.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 29, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/0001628280-23-009629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.